01 8Nuedexta
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 226
2019 Revenue in Millions : 251
Growth (%) : -10
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 216
2020 Revenue in Millions : 217
Growth (%) : 8
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 215
2021 Revenue in Millions : 216
Growth (%) : -1
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 196
2022 Revenue in Millions : 215
Growth (%) : 4
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2016 Revenue in Millions : 216
2015 Revenue in Millions : 171
Growth (%) : 26
Dextromethorphan and Quinidine
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 246
2016 Revenue in Millions : 227
Growth (%) : 8
Dextromethorphan and Quinidine
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 230
2017 Revenue in Millions : 230
Growth (%) : -39%
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 246
2018 Revenue in Millions : 237
Growth (%) : 4
LOOKING FOR A SUPPLIER?